Matthew Mintz
Internal Medicine · Bethesda, MDNPI 1063584951
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (49.9%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by GSK at 58.9% of the total. Reporting peaked in 2019 at $40,034 and has fallen 92.1% since, to $3,148 in 2025. Among internal medicine clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 226 payments — averaging $598.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$80K
- Boehringer Ingelheim$21K
- Novo Nordisk$19K
- Bayer$8K
- Teva Pharmaceuticals USA, Inc.$3K
- Johnson & Johnson$2K
- plus $3K from 21 others
Across 276 payments — averaging $3829.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$999K
- Teva Pharmaceuticals USA, Inc.$24K
- GSK$19K
- BD$15K
What the payments were for
- Consulting fees$59,00944%
- Speaking & faculty fees$67,41250%
- Travel & lodging$5,5224%
- Food & beverage$3,2192%
- Education$260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 91 | $79,609 |
| Boehringer Ingelheim | 15 | $20,909 |
| Novo Nordisk | 24 | $18,613 |
| Bayer | 11 | $8,215 |
| Teva Pharmaceuticals USA, Inc. | 5 | $3,219 |
| Johnson & Johnson | 5 | $1,743 |
| AstraZeneca | 22 | $1,129 |
| Genentech, Inc. | 1 | $810 |
| Lilly USA, LLC | 16 | $309 |
| Currax Pharmaceuticals LLC | 5 | $81 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $64 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $58 |
| AbbVie(2 entities) | 3 | $55 |
| Corcept Therapeutics | 2 | $39 |
| Antares Pharma, Inc. | 2 | $38 |
| Pfizer | 2 | $37 |
| Redhill Biopharma Inc. | 2 | $35 |
| Janssen Scientific Affairs, LLC | 1 | $34 |
| IBSA Pharma Inc. | 2 | $34 |
| Arbor Pharmaceuticals, Inc. | 2 | $33 |
| Merck | 1 | $25 |
| Inspire Medical Systems, Inc. | 1 | $19 |
| Eisai Inc. | 1 | $18 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
| Acella Pharmaceuticals, LLC | 1 | $16 |
| Tolmar, Inc. | 1 | $15 |
| Biohaven Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$43,681
- RYBELSUS$9,761
- NUCALA$9,110
- ANORO$8,194
- Kerendia$8,120
- ANORO ELLIPTA$7,703
- SPIRIVA$7,680
- STIOLTO$6,302
- Victoza$5,201
- STIOLTO RESPIMAT$1,920
- SPRAVATO$1,625
- BREZTRI$740
- Ozempic$578
How this compares
$135,186 in reported general payments places this provider in the 95th percentile of 2,979 internal medicine providers in Maryland.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $28,427 |
| MounjaroTirzepatide | 22 | $23,404 |
| JardianceEmpagliflozin | 20 | $21,014 |
| FarxigaDapagliflozin Propanediol | 18 | $15,701 |
| MyrbetriqMirabegron | 16 | $7,197 |
| VyvanseLisdexamfetamine Dimesylate | 12 | $6,866 |
| Dexlansoprazole DrDexlansoprazole | 14 | $2,227 |
| Rosuvastatin Calcium | 112 | $2,185 |
| Duloxetine Hcl | 73 | $2,006 |
| SynthroidLevothyroxine Sodium | 28 | $1,482 |
| Tamsulosin Hcl | 60 | $1,458 |
| Ipratropium Bromide | 12 | $1,257 |
| Olmesartan Medoxomil | 30 | $940 |
| Amlodipine-ValsartanAmlodipine Besylate/Valsartan | 13 | $767 |
| Atorvastatin Calcium | 84 | $730 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $79,609 | $28,42725 claims |
| Lilly USA, LLCMounjaro | $309 | $23,40422 claims |
| Boehringer IngelheimJardiance | $20,909 | $21,01420 claims |
| AstraZenecaFarxiga | $1,129 | $15,70118 claims |
| AbbVieSynthroid | $55 | $1,48228 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,979 internal medicine providers in Maryland.
Other internal medicine in Bethesda
- Micaela IantornoBethesda$26K
- Marianne MannHighland$2.1M
- Param DedhiaBaltimore$636K
- Curtis RosebraughAshton$418K
- Mark CorriereColumbia$402K
- Gregory PokrywkaTowson$377K
- Shawn DhillonBaltimore$227K
- Brian HarveyAnnapolis$220K
- Jeremy SugarmanBaltimore$210K
- Florence HounPotomac$161K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.